Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment

Bibliography

• A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-32
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Bliss P, Graham JD, A phase III study of Doxil/Caelyx versus paclitaxel in platinum treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002, abstract 808
   Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;7:3312-22
   Google Scholar
• Gordon AN, Tonda M, Sun S, Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D, Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26:890-96
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Savarese A, Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology 2009;76:49-54
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmac Rev 2004;56:185-229
   PubMed Web of Science ®Google Scholar
• Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219-52
   PubMedGoogle Scholar
• Ashley N, Poulton J. Mitochondrial DNA is a direct target of anticancer anthracycline drugs. Biochem Biophys Res Commun 2009;378:450-5
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41
   PubMed Web of Science ®Google Scholar
• Huang KJ. Liposome pharmacokinetics. In: Ostro MJ, editor, Liposomes from Biophysics to Therapeutics. Marcel Dekker, New York; 1987. p. 109-56
   Google Scholar
• Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 2003;8:237-49
   Google Scholar
• Lipp HP, Bokemeyer C. Anthracyclines and other intercalating agents. In: Lipp HP, editor, Anticancer drug toxicity: prevention, management and clinical pharmacokinetics. Marcel Dekker, New York; 1999. p. 81-113
   Google Scholar
• Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001;7:223-5
   PubMed Web of Science ®Google Scholar
• Amantea MA, Forrest A, Northfelt DW, Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 1997;61:301-11
   PubMed Web of Science ®Google Scholar
• Twelves CJ, Dobbs NA, Gillies HC, Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 1998;42:229-34
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Planting AS, Jewell RC, Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 1999;10:719-28
   PubMed Web of Science ®Google Scholar
• Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008;8:21-32
   PubMedGoogle Scholar
• Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99
   PubMed Web of Science ®Google Scholar
• Gabizon A, Goren D, Horowitz AT, Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997;24:337-44
   Web of Science ®Google Scholar
• Working PK, Dayan AD. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 1996;15:751-85
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin review of animal and human studies. Clin Pharmacokinet 2003;42:419-36
   PubMed Web of Science ®Google Scholar
• DoxilR (doxorubicin HCl liposome injection) [package insert]. Raritan NJ, editor, Ortho Biotech Products L.P; 2006
   Google Scholar
• Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 1997;11:11-32
   Google Scholar
• Gabizon A, Isacson R, Rosengarten O, An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008;61:695-702
   PubMed Web of Science ®Google Scholar
• Ishida T, Atobe K, Wang X, Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin encapsulation and high-dose first injection. J Control Release 2006;115:251-8
   PubMed Web of Science ®Google Scholar
• Strother R, Matei D. Pegylated liposomal doxorubicin in ovarian cancer. Ther Clin Risk Manag 2009;5:639-50
   PubMedGoogle Scholar
• Li Y, Finkel KW, Hu W, Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol 2007;106:375-80
   PubMed Web of Science ®Google Scholar
• Legha SS, Benjamin RS, Mackay B, Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337-51
   PubMed Web of Science ®Google Scholar
• Alberts DS, Muggia FM, Carmichael J, Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004;31:53-90
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Lyass O, Berry GJ, Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004;22:663-9
   PubMed Web of Science ®Google Scholar
• Lotem M, Hubert A, Lyass O, Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000;136:1475-80
   PubMed Web of Science ®Google Scholar
• Chou HH, Wang KL, Chen CA, Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynaecologic oncology group study with long-term follow-up. Gynecol Oncol 2006;101:423-8
   PubMed Web of Science ®Google Scholar
• Lyass O, Uziely B, Ben-Yosef R, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-47
   PubMed Web of Science ®Google Scholar
• Campos SM, Matulonis UA, Penson RT, Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 2003;90:610-18
   PubMed Web of Science ®Google Scholar
• Hong RL, Tseng YL. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003;51:433-8
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for First-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9
   PubMed Web of Science ®Google Scholar
• Lopez AM, Wallace L, Dorr RT, Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303-06
   PubMed Web of Science ®Google Scholar
• Amantea M, Newman MS, Sullivan TM, Relationship of dose intensity to the induction of palmar–plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999;18:17-26
   PubMed Web of Science ®Google Scholar
• Lyass O, Hubert A, Gabizon AA. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 2001;7:3040-46
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Karavasilis V, Tzamakou E, Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs 2002;13:481-9
   PubMed Web of Science ®Google Scholar
• Hong RL, Huang CJ, Tseng YL, Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumorbearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 1999;5:3645-52
   PubMed Web of Science ®Google Scholar
• Rose PG, Maxson JH, Fusco N, Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323-8
   PubMed Web of Science ®Google Scholar
• Tanyi JL, Smith JA, Ramos L, Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol 2009;114:219-24
   PubMed Web of Science ®Google Scholar
• Lorusso D, Naldini A, Testa A, Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 2004;67:243-9
   PubMed Web of Science ®Google Scholar
• Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005;10:205-14
   PubMed Web of Science ®Google Scholar
• Von Moos R, Thuerlimann BJ, Aapro M, Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008;44:781-90
   PubMed Web of Science ®Google Scholar
• Strauss HG, Hemsen A, Karbe I, Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs 2008;19:541-5
   PubMed Web of Science ®Google Scholar
• Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Anticancer Res 2008;28:1329-34
   PubMed Web of Science ®Google Scholar
• Sehouli J, Camara O, Schmidt M, North-Eastern German Society of Gynecological Oncology. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Cancer Chemother Pharmacol 2009;64:585-91
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Corrado G, Licameli A, Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag 2010;6:463-83
   PubMed Web of Science ®Google Scholar
• Schwonzen M, Kurbacher CM, Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000;11:681-85
   PubMed Web of Science ®Google Scholar
• Androulakis N, Kouroussis C, Mavroudis D, Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. Eur J Cancer 2002;38:1992-97
   PubMed Web of Science ®Google Scholar
• Sikov WM, Hsieh M, Lopez F. Phase I weekly docetaxel with doxorubicin or Doxil: a BrUOG study. Proc Am Soc Clin Oncol 2001;20: abstract 2088
   Google Scholar
• Holmes FA, Rowinsky EK. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 2001;28:8-14
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Karavasilis V, Tzamakou E, Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs 2002;13:481-9
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Karavasilis V, Tzamakou E, Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 2004;53:452-7
   PubMed Web of Science ®Google Scholar
• Goncalves A, Braud AC, Viret F, Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res 2003;23:3543-8
   PubMed Web of Science ®Google Scholar
• du Bois A, Burges A, Meier W, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann Oncol 2006;17:93-6
   PubMed Web of Science ®Google Scholar
• Hubert A, Lyass O, Pode D, Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormonerefractory prostate cancer. Anticancer Drugs 2000;11:123-7
   PubMed Web of Science ®Google Scholar
• Rose PG, Greer BE, Horowitz IR, Paclitaxel, carboplatin, and pegylated liposomal doxorubicin in ovarian, and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 2007;104:114-19
   PubMed Web of Science ®Google Scholar
• Gibbs DD, Pyle L, Allen M, A phase I dose-finding study of a combination of Pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer 2002;86:1379-84
   PubMed Web of Science ®Google Scholar
• Tas F, Derin D, Guney N, Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum sensitive epithelial ovarian cancer. Int J Clin Oncol 2008;13:330-4
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Vorobiof DA, Slabber C, Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum- sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009;19:1137-41
   PubMed Web of Science ®Google Scholar
• Ferrero JM, Weber B, Geay JF, Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007;18:263-8
   PubMed Web of Science ®Google Scholar
• Power P, Stuart G, Oza A, Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 2009;114:410-14
   PubMed Web of Science ®Google Scholar
• Weber B, Lortholary A, Mayer F, Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 2009;29:4195-200
   PubMedGoogle Scholar
• Recchia F, Saggio G, Amiconi G, A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol 2007;106:164-9
   PubMed Web of Science ®Google Scholar
• Dalla Palma M, Lombardi G, Donach ME, Tolerability of PLD/Oxaliplatin Regimen in Recurrent Ovarian Cancer Patients With Previous Fragility to Carboplatin/Paclitaxel Treatment. Am J Clin Oncol. 8 July 2010 [Epub ahead of print] DOI: 10.1097/COC.0b013e3181e1cb22
   Google Scholar
• Nicoletto MO, Falci C, Pianalto D, Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol 2006;100:318-23
   PubMed Web of Science ®Google Scholar
• Valerio MR, Tagliaferri P, Raspagliesi F, A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 2006;16:79-85
   PubMed Web of Science ®Google Scholar
• Garcia AA, Roman L, Muderspach L, Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer Invest 2005;23:665-70
   PubMed Web of Science ®Google Scholar
• Rose PG, Smrekar M, Haba P, A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Am J Clin Oncol 2008;31:476-80
   PubMed Web of Science ®Google Scholar
• Verhaar-Langereis M, Karakus A, van Eijkeren M, Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65-70
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Blum KA, Tan BR, Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer 2002;95:2223-9
   PubMed Web of Science ®Google Scholar
• Bozionelou V, Vamvakas L, Pappas P, A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Br J Cancer 2007;97:43-9
   PubMed Web of Science ®Google Scholar
• Ichiki M, Gohara R, Fujiki R, Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003;52:67-72
   PubMed Web of Science ®Google Scholar
• Tas F, Guney N, Derin D, A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Int J Clin Oncol 2008;13:156-60
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Paris I, Ludovisi M, Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol 2005;98:267-73
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-18
   PubMed Web of Science ®Google Scholar
• Harrison LE, Bryan M, Pliner L, Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol 2008;15:1407-13
   PubMed Web of Science ®Google Scholar
• Katsaros D, Oletti MV, Rigault de la Longrais IA, Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. Ann Oncol 2005;16:300-6
   PubMed Web of Science ®Google Scholar
• Joly F, Sevin E, Lortholary A, Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol 2010;116:312-16
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler N, del Campo J, Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009;45:2324-32
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler NJ, Hall JB, Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2010;20:772-80
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Levenback CF, Ramirez PT, Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Onc 2010;3:9-20
   PubMed Web of Science ®Google Scholar
• von Mehren M, Schilder RJ, Cheng JD, A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008;19:1802-9
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107-14
   PubMed Web of Science ®Google Scholar
• Muggia FM, Boyd L, Liebes L, Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): pharmacokinetics (PK), safety, and preliminary outcome results. Proc Am Soc Clin Oncol 2009: abstract 5548
   Google Scholar
• Kikuchi Y, Kouta H, Kikuchi R., Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer. Proc Am Soc Clin Oncol 2009: abstract 5547
   Google Scholar
• Vergote I, Colombo N, Kutarska E, Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. Proc Am Soc Clin Oncol 2009: abstract 5560
   Google Scholar